Capstone Investment Advisors
AMLX icon

Capstone Investment Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Capstone Investment Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,634
Closed -$145K – 1565
2025
Q3 		$145K Buy
+10,634
New +$100K ﹤0.01% 1857
2025
Q2 		– Sell
-16,150
Closed -$57.2K – 1566
2025
Q1 		$57.2K Buy
+16,150
New +$57.5K ﹤0.01% 1293
2024
Q2 		– Sell
-80,084
Closed -$227K – 2059
2024
Q1 		$227K Buy
80,084
+60,084
+300% +$786K ﹤0.01% 1961
2023
Q4 		$294K Sell
20,000
-2,829
-12% -$43.4K ﹤0.01% 1599
2023
Q3 		$418K Buy
+22,829
New +$483K ﹤0.01% 1422
2023
Q2 		– Sell
-10,150
Closed -$298K – 1831
2023
Q1 		$298K Buy
+10,150
New +$353K ﹤0.01% 1172

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capstone Investment Advisors's AMLX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 10,634 shares — an estimated $145K sold.

Capstone Investment Advisors first reported a position in AMLX in Q1 2023 and held it in 6 quarters. The position peaked at $418K in Q3 2023. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 10,634 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $145K.
  • Capstone Investment Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Capstone Investment Advisors's Amylyx Pharmaceuticals position peaked at $418K in Q3 2023.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.